Machatha Stephen, Chief Development Officer at Aldeyra Therapeutics ($ALDX), made one open market sale of company shares in the last year, totaling $113,713 on August 11, 2025. This ranks 9,380th among 11,678 insiders, well below the average sale of $8.6 million over about six transactions. Machatha Stephen recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 11, 2025 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | S | Common Stock | 22073 | $5.15 | 221,799.0000 | 59,708,654 | 9.05% | 0.04% |
| March 4, 2025 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | A | Stock Option (right to buy) | 202427 | $0.00 | 202,427.0000 | 59,708,654 | 9999.99% | 0.34% |
| Aug. 12, 2024 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | S | Common Stock | 16041 | $4.74 | 236,771.0000 | 0 | 6.35% | 0.00% |
| March 12, 2024 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | S | Common Stock | 11537 | $3.16 | 252,812.0000 | 0 | 4.36% | 0.00% |
| March 9, 2024 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | A | Stock Option (right to buy) | 405450 | $0.00 | 405,450.0000 | 0 | 9999.99% | 0.00% |
| March 11, 2024 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | S | Common Stock | 18231 | $3.41 | 255,243.0000 | 0 | 6.67% | 0.00% |
| March 12, 2024 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | S | Common Stock | 11537 | $3.16 | 243,706.0000 | 0 | 4.52% | 0.00% |
| Feb. 28, 2023 | Aldeyra Therapeutics, Inc. | $ALDX | Machatha Stephen | Chief Development Officer | A | Stock Option (right to buy) | 220258 | $0.00 | 220,258.0000 | 0 | 9999.99% | 0.00% |